FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 202 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... October 3, 2022 Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer March 28, 2019 ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Load more HOT NEWS Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom DeFi Trial: Smart Design and Impressive Results For the Benefit of... ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany
